ストックスクリーナーアプリを入手
762.33
3.01%
22.26
前日終値:
$740.07
開ける：
$746.82
24時間の取引高:
4.86M
Relative Volume:
1.27
時価総額：
$722.49B
収益：
$49.00B
当期純損益:
$11.11B
株価収益率:
62.03
EPS:
12.29
ネットキャッシュフロー:
$-1.27B
1週間 パフォーマンス:
-6.20%
1か月 パフォーマンス:
-1.75%
6か月 パフォーマンス:
-6.01%
1年 パフォーマンス:
-8.42%
1日の値動き範囲:
$745.99
$768.00
1週間の範囲:
$735.44
$820.22
52週間の値動き範囲:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
LLY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-05 | ダウングレード | Erste Group | Buy → Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Reduce |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-09-13 | 再開されました | Citigroup | Buy |
| 2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
| 2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
| 2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
| 2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-10-20 | 再開されました | UBS | Buy |
| 2023-08-09 | アップグレード | Jefferies | Hold → Buy |
| 2023-07-26 | 繰り返されました | Citigroup | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-24 | 繰り返されました | BofA Securities | Buy |
| 2023-05-24 | 繰り返されました | UBS | Buy |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-11-18 | 開始されました | Credit Suisse | Outperform |
| 2022-09-22 | アップグレード | UBS | Neutral → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-04-06 | 再開されました | Morgan Stanley | Overweight |
| 2022-03-10 | 開始されました | Daiwa Securities | Outperform |
| 2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
| 2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
| 2021-12-17 | 開始されました | Goldman | Neutral |
| 2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-12-16 | 繰り返されました | BofA Securities | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-10-11 | アップグレード | Berenberg | Hold → Buy |
| 2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
| 2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
| 2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-21 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
| 2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-03-12 | 開始されました | JP Morgan | Overweight |
| 2019-01-23 | 開始されました | UBS | Buy |
| 2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
| 2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2018-10-01 | 繰り返されました | SunTrust | Buy |
| 2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
The GLP-1 Gold Rush: Assessing the Financial Implications of Expanded Medicaid and Medicare Coverage for Eli Lilly and Novo Nordisk - AInvest
Why Eli Lilly Stock Topped the Market Today - The Motley Fool
Why Novo Nordisk Stock Bumped Higher on Friday - The Motley Fool
Here’s Why Eli Lilly And Novo Nordisk Stocks Are Rallying Today - Stocktwits
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and AbbVie (ABBV) - The Globe and Mail
Lilly, Novo rally after report of Medicare weight loss coverage - TipRanks
U.S. Medicare plans to cover Eli Lilly and Co and Novo-Nordisk A/S GLP-1 weight loss drugs, with a pilot program set to begin in 2026. - 富途牛牛
Positive Outlook for Eli Lilly & Co. Amid Key Trial Outcomes and Earnings Projections - TipRanks
Eli Lilly price breaches upward correctional trend lineForecast today01-08-2025 - Economies.com
Eli Lilly: The Worst May Be Already Over (Earnings Preview) (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) Stock Rises on Medicare Weight Loss Drug Coverage Plan - GuruFocus
Exxon Mobil, Eli Lilly, Moderna - TradingView
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued? - Morningstar
Eli Lilly and Company’s Mounjaro Displayed Cardiovascular Protection in New Head-to-Head Trial - PharmExec
Eli Lilly (LLY) Bulls Prepare for Multiyear Upside - TipRanks
Eli Lilly and Company (LLY): We Sold Some Lilly, Says Jim Cramer - Insider Monkey
Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs - Reuters
Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results - simplywall.st
Trial Finds Eli Lilly’s (LLY) Diabetes Drug Mounjaro Has Heart Health Benefits - TipRanks
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Lilly’s Mounjaro as Effective on Heart Risks as Older Drug - Bloomberg
What Makes Eli Lilly and Company (LLY) a Lucrative Investment? - Insider Monkey
Lilly’s Mounjaro shows cardiovascular benefits in diabetes study - Investing.com
Lilly’s Mounjaro shows cardiovascular benefits in diabetes study By Investing.com - Investing.com India
Mounjaro proves more heart protective than Trulicity in trial of Eli Lilly diabetes drugs - Reuters
Eli Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment - statnews.com
Eli Lilly’s stock drops as Trump targets 17 drug makers with letters on their pricing - MarketWatch
Extension trial demonstrates long-term benefit for Lilly Alzheimer’s drug - European Pharmaceutical Review
Eli Lilly and Company (LLY): Jim Cramer’s “Bullish” On News Of Tariffs - Insider Monkey
Eli Lilly Stock (LLY) Will Benefit from ‘Onshoring Boom,’ Says BMO Capital Markets - TipRanks
Eisai/Biogen, Eli Lilly highlight long-term data backing Alzheimer’s drugs - Seeking Alpha
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease - Eli Lilly
Dermatology Conditions, Information & Resources - Eli Lilly
Eli Lilly Pulls Ahead In Weight-Loss Drug Race - Finimize
Novo Nordisk's stock plummets 21% as Eli Lilly faces market fluctuations in KoreaCHOSUNBIZ - Chosunbiz
Fat jab wars wipe £70bn off Ozempic maker Novo Nordisk as it feels the heat from rival Eli Lilly - MSN
Eli Lilly's CEO Pay and Its Implications for Pharma Innovation and Shareholder Value - AInvest
Assessing Eli Lilly's CEO Pay Surge: Innovation-Driven Growth and Shareholder Value Alignment - AInvest
Why Eli Lilly Stock Was Looking Sickly Today - AOL.com
Eli Lilly (LLY) Stock Dips on Novo Nordisk Guidance Update - GuruFocus
Lilly set for strong quarter after Novo profit warning - Reuters
Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results - insights.citeline.com
Why Eli Lilly (LLY) Stock Is Falling Today - Yahoo Finance
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Tuesday By Investing.com - Investing.com India
UnitedHealth, Eli Lilly Lead Market Cap Stock Movers on Tuesday - Investing.com
Eli Lilly (LLY) Announces Positive Results For Jaypirca In Phase 3 Trial - Yahoo Finance
Eli Lilly strikes again in weight-loss drugs fight - Life Sciences Intellectual Property Review
What's Going On With Eli Lilly Stock On Tuesday? - inkl
Eli Lilly’s New Study on LY4088044: What Investors Need to Know - TipRanks
Eli Lilly (LLY) Maintains Strong Outlook Amid Competitor's Guidance Update - GuruFocus
JPMorgan does not see Lilly read-through from Novo cut - TipRanks
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
1.57%
大文字化:
|
ボリューム (24 時間):